Abstract
Glomerular remodelling, i.e. cell and matrix turnover, is a permanent process even in the normal kidney. Within the glomerulus, two cell types, namely the endothelial and mesangial cell, exhibit relatively high turnover and thus high capacity to regenerate following injury, whereas podocytes appear to be in a state of growth arrest with very limited potential for mitosis and apparently even lesser potential for complete cell division. An understanding of how these processes are regulated by growth factors may allow novel therapeutic approaches aimed at deviating the response to injury from the scaring pathway to reconstitution of normal glomerular morphology. Out of the apparently chaotic network of cytokines and growth factors some factors have evolved, which exhibit well-defined actions in the glomerulus that renders them attractive targets for interventions. These include platelet-derived growth factor (PDGF), a central mediator of mesangial cell proliferation and matrix synthesis, vascular endothelial growth factor (VEGF), a central angiogenic mediator regulating endothelial cell proliferation and survival and finally hepatocyte growth factor (HGF), an angiogenic growth factor with additional pronounced activity at the tubulointerstitial level.
References
1.
Pabst R, Sterzel RB: Cell renewal of glomerular cell types in normal rats. An autoradiographic analysis. Kidney Int 1983;24:626–631.
2.
Ostendorf T, Kunter U, Groene HJ, Kawachi H, Shimizu F, Koch KM, Janjic N, Floege J: Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2001;12:909–918.
3.
Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916–927.
4.
Floege J, Johnson RJ, Alpers CE, Fatemi-Nainie S, Richardson CA, Gordon K, Couser WG: Visceral glomerular epithelial cells can proliferate in vivo and synthesize platelet-derived growth factor B-chain. Am J Pathol 1993;142:637–650.
5.
Kriz W, Hahnel B, Rosener S, Elger M: Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 1995;48:1435–1450.
6.
Nagata M, Yamaguchi Y, Komatsu Y, Ito K: Mitosis and the presence of binucleate cells among glomerular podocytes in diseased human kidneys. Nephron 1995;70:68–71.
7.
Nagata M, Nakayama K, Terada Y, Hoshi S, Watanabe T: Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol 1998;153:1511–1520.
8.
Shankland SJ, Floege J, Thomas SE, Nangaku M, Hugo C, Pippin J, Henne K, Hockenberry DM, Johnson RJ, Couser WG: Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 1997;52:404–413.
9.
Shankland SJ: Cell cycle regulatory proteins in glomerular disease. Kidney Int 1999;56:1208–1215.
10.
Johnson R, Iida H, Yoshimura A, Floege J, Bowen-Pope DF: Platelet-derived growth factor: a potentially important cytokine in glomerular disease. Kidney Int 1992;41:590–594.
11.
Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283–1316.
12.
Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U: PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000;2:302–309.
13.
Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U: PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001;3:512–516.
14.
Gilbertson DG, Duff ME, West JW, Kelly JD, Sheppard PO, Hofstrand PD, Gao Z, Shoemaker K, Bukowski TR, Moore M, Feldhaus AL, Humes JM, Palmer TE, Hart CE: Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 2001;276:27407–27414.
15.
LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, Sullivan C, Boldog FL, Yang M, Vernet C, Burgess CE, Fernandes E, Deegler LL, Rittman B, Shimkets J, Shimkets RA, Rothberg JM, Lichenstein HS: PDGF-D, a new protease-activated growth factor. Nat Cell Biol 2001;3:517–521.
16.
Eitner F, Ostendorf T, Van Roeyen C, Kitahara M, Li X, Aase K, Groene HJ, Eriksson U, Floege J: Expression of a novel PDGF isoform, PDGF-C, in normal and diseased rat kidney. J Am Soc Nephrol 2002, in press.
17.
Floege J, Johnson RJ: Multiple roles for platelet-derived growth factor in renal disease. Miner Electrolyte Metab 1995;21:271–282.
18.
Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992;175:1413–1416.
19.
Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic N: Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 1999;154:169–179.
20.
Ostendorf T, Kunter U, Dooley S, Janjic N, Ruckman J, Eitner F, Floege J: The effects of PDGF antagonism in experimental glomerulonephritis are independent of the TGF-beta system. J Am Soc Nephrol 2001;13:658–667.
21.
Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001;59:1324–1332.
22.
Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938–1942.
23.
Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527–543.
24.
Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359–1364.
25.
Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G: VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997;272:7151–7158.
26.
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9–22.
27.
Noguchi K, Yoshikawa N, Ito-Kariya S, Inoue Y, Hayashi Y, Ito H, Nakamura H, Iijima K: Activated mesangial cells produce vascular permeability factor in early-stage mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998;9:1815–1825.
28.
Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger DD, Janjic N, Floege J: VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999;104:913–923.
29.
Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, Johnson RJ: Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000;58:2390–2399.
30.
Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model. ii. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001;12:1448–1457.
31.
de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993–1000.
32.
Benjamin LE: Glucose, VEGF-A, and diabetic complications. Am J Pathol 2001;158:1181–1184.
33.
Vargas GA, Hoeflich A, Jehle PM: Hepatocyte growth factor in renal failure: promise and reality. Kidney Int 2000;57:1426–1436.
34.
Matsumoto K, Nakamura T: Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001;59:2023–2038.
35.
Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997;94:701–706.
36.
Cantley LG, Cantley LC: Signal transduction by the hepatocyte growth factor receptor, c-met. Activation of the phosphatidylinositol 3-kinase. J Am Soc Nephrol 1995;5:1872–1881.
37.
Mori T, Shimizu A, Masuda Y, Ohashi R, Sugisaki Y, Yamanaka N: Hepatocyte growth factor stimulates endothelial cell proliferation and accelerates angiogenic glomerular capillary repair in experimental progressive glomerulonephritis (abstract). J Am Soc Nephrol 2000;11:495A.
38.
Yang XM, Park M: Expression of the hepatocye growth factor/scatter factor receptor tyrosine kinase is localized to epithelia in the adult mouse. Lab Invest 1995;73:483–491.
39.
Mizuno S, Matsumoto K, Nakamura T: Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 2001;59:1304–1314.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
